OncoMatch/Clinical Trials/NCT07130032
Efficacy And Safety Of Anti-PD-1/PD-L1 Antibodies In Combination With Bevacizumab And Metronomic Cyclophosphamide In Patients With Non-Small Cell Lung Cancer And Cutaneous Melanoma Previously Treated With Immune Checkpoint Blockade
Is NCT07130032 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments including reICB regimen (NSCLC) and reICB regimen (melanoma) for metastatic non-small cell lung cancer (nsclc).
Treatment: reICB regimen (NSCLC) · reICB regimen (melanoma) — This study will evaluate efficacy and safety of anti-PD-1/PD-L1 antibodies combined with bevacizumab and metronomic cyclophosphamide in patients with metastatic non-small cell lung cancer (NSCLC) and cutaneous melanoma previously treated with immune checkpoint blockade (ICB). The hypotheses of this study are that a combination of ICB, cyclophosphamide, and bevacizumab prolongs progression-free survival and overall survival, and also increases rates of objective responses and disease control.
Check if I qualifyExtracted eligibility criteria
Cancer type
Non-Small Cell Lung Carcinoma
Melanoma
Biomarker criteria
Required: EGFR wild-type
No mutations in the EGFR gene (in case of NSCLC).
Required: ALK wild-type
No mutations in the ... ALK ... (in case of NSCLC).
Required: ROS1 wild-type
No mutations in the ... ROS1 ... (in case of NSCLC).
Required: RET wild-type
No ... RET gene translocations (in case of NSCLC).
Allowed: BRAF V600 mutation
If the patient had the BRAF V600 mutation, they were also treated with BRAF and MEK inhibitors.
Disease stage
Metastatic disease required
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Must have received: anti-PD-1 therapy — metastatic NSCLC
previously received anti-PD-(L)1 antibodies in combination with platinum-containing chemotherapy either in the first line or sequentially in the first and second lines for the treatment of metastatic disease
Must have received: platinum-based chemotherapy — metastatic NSCLC
previously received anti-PD-(L)1 antibodies in combination with platinum-containing chemotherapy either in the first line or sequentially in the first and second lines for the treatment of metastatic disease
Must have received: anti-PD-1 therapy — metastatic Skin Melanoma
previously received anti-PD-1 antibodies either in combination with or without anti-CTLA4 therapy for metastatic disease. If the patient had the BRAF V600 mutation, they were also treated with BRAF and MEK inhibitors.
Must have received: anti-CTLA-4 therapy — metastatic Skin Melanoma
previously received anti-PD-1 antibodies either in combination with or without anti-CTLA4 therapy for metastatic disease
Must have received: BRAF inhibitor — metastatic Skin Melanoma with BRAF V600 mutation
If the patient had the BRAF V600 mutation, they were also treated with BRAF and MEK inhibitors.
Must have received: MEK inhibitor — metastatic Skin Melanoma with BRAF V600 mutation
If the patient had the BRAF V600 mutation, they were also treated with BRAF and MEK inhibitors.
Lab requirements
Blood counts
ANC ≥1.5×10^9/L, platelet count ≥100×10^9/L, hemoglobin ≥9.0 g/dL
Kidney function
Serum creatinine ≤1.5 × ULN
Liver function
Serum total bilirubin ≤1.5 × ULN (Gilbert syndrome: <2 × ULN and normal AST/ALT); ALT or AST ≤3 × ULN
ANC <1.5×10^9/L, platelet count <100×10^9/L, or hemoglobin <9.0 g/dL. Serum total bilirubin >1.5 × ULN. Participants with Gilbert syndrome, bilirubin <2 X ULN, and normal AST/ALT are eligible; ALT or AST >3 × ULN; Serum creatinine >1.5 × ULN.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify